These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37610062)

  • 1. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Hagi K; Nitta M; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Dubourg J; Ueki K; Grouin JM; Fouqueray P
    Diabetes Obes Metab; 2021 Mar; 23(3):800-810. PubMed ID: 33275318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Sep; 14(9):1101-1109. PubMed ID: 37264517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
    Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
    Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
    Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
    Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
    Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
    Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
    Pirags V; Lebovitz H; Fouqueray P
    Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
    Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
    Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.
    Permana H; Soetedjo NNM; Yanto TA; Tendean M; Hariyanto TI; Suastika K
    Expert Rev Endocrinol Metab; 2024; 19(1):89-98. PubMed ID: 38047423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
    Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
    BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
    Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
    Johansson KS; Brønden A; Knop FK; Christensen MB
    Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38794986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK; Lereun C; Wright D
    Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.